Monte Rosa Therapeutics (NASDAQ:GLUE) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Monte Rosa Therapeutics (NASDAQ:GLUE) issued its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05), FiscalAI reports. Monte Rosa Therapeutics had a negative return on equity of 48.30% and a negative net margin of 560.85%.The business had revenue of $8.97 million for the quarter, compared to analyst estimates of $12.91 million.

Monte Rosa Therapeutics Stock Performance

Shares of GLUE stock traded up $0.17 on Friday, reaching $15.88. 1,031,388 shares of the company were exchanged, compared to its average volume of 1,631,805. The company has a market cap of $1.34 billion, a price-to-earnings ratio of -9.02 and a beta of 1.59. Monte Rosa Therapeutics has a 1 year low of $4.12 and a 1 year high of $25.77. The business has a 50-day moving average price of $20.53 and a 200 day moving average price of $19.35.

Insider Transactions at Monte Rosa Therapeutics

In other Monte Rosa Therapeutics news, insider Filip Janku sold 5,407 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of $24.50, for a total transaction of $132,471.50. Following the completion of the sale, the insider directly owned 60,612 shares in the company, valued at approximately $1,484,994. The trade was a 8.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Sharon Townson sold 6,000 shares of the stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $23.31, for a total value of $139,860.00. Following the transaction, the insider directly owned 67,845 shares of the company’s stock, valued at $1,581,466.95. The trade was a 8.13% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 81,778 shares of company stock valued at $1,768,581. 6.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Monte Rosa Therapeutics

Large investors have recently modified their holdings of the business. Virtu Financial LLC raised its position in shares of Monte Rosa Therapeutics by 56.6% in the fourth quarter. Virtu Financial LLC now owns 18,717 shares of the company’s stock valued at $293,000 after buying an additional 6,765 shares during the last quarter. Invesco Ltd. boosted its position in Monte Rosa Therapeutics by 270.0% during the fourth quarter. Invesco Ltd. now owns 362,213 shares of the company’s stock worth $5,680,000 after acquiring an additional 264,315 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in Monte Rosa Therapeutics during the 4th quarter valued at about $172,000. Empowered Funds LLC grew its stake in Monte Rosa Therapeutics by 218.0% during the 4th quarter. Empowered Funds LLC now owns 278,077 shares of the company’s stock valued at $4,360,000 after acquiring an additional 190,627 shares in the last quarter. Finally, Voloridge Investment Management LLC acquired a new stake in Monte Rosa Therapeutics in the 4th quarter valued at about $561,000. Hedge funds and other institutional investors own 79.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on GLUE. JPMorgan Chase & Co. lowered their target price on shares of Monte Rosa Therapeutics from $31.00 to $27.00 and set an “overweight” rating for the company in a research note on Friday. Zacks Research upgraded shares of Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Wedbush lowered their price target on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a report on Monday, August 3rd. Jefferies Financial Group reissued a “buy” rating on shares of Monte Rosa Therapeutics in a report on Monday, July 27th. Finally, Weiss Ratings upgraded shares of Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $28.50.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.